Localized Microrobotic Delivery of Enzyme‐Responsive Hydrogel‐Immobilized Therapeutics to Suppress Triple‐Negative Breast Cancer
Small · 2025-05 · 21 (18)
DOI: 10.1002/smll.202408813 ↗Kurz gefasst
Fachartikel in der Zeitschrift Small, online erschienen am 18.12.2024. Verfasst von Mingzhen Tian und 4 weiteren Autor:innen. Beteiligte Einrichtung: Institute of Medical Robotics, School of Biomedical Engineering, Shanghai Jiao Tong University, Shanghai, 200240, China. Hauptthemen laut MEDLINE: Triple Negative Breast Neoplasms, Hydrogels, Drug Delivery Systems. Die Arbeit wurde bisher 37-mal zitiert (Crossref) und nennt 43 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Shanghai Municipal Science and Technology Major Project.
Abstract (Originalsprache)
Triple‐negative breast cancer (TNBC), characterized by its aggressive metastatic propensity and lack of effective targeted therapeutic options, poses a major challenge in oncological management. A proof‐of‐concept neoadjuvant strategy aimed at inhibiting TNBC tumor growth and mitigating metastasis through a localized delivery of chemotherapeutics is reported in this paper. This approach addresses the limitations in payload capacity and stimuli responsiveness commonly associated with microrobotics in oncology. A hydrogel‐based system is developed for the immobilization of chemotherapeutic agents, subsequently encapsulated within magnetically responsive microrobots. This design leverages external magnetic fields to facilitate the precise navigation and localization of the therapeutic agents directly to the tumor site. The efficacy of this approach is demonstrated in an animal model, in which a significant 14‐fold reduction in tumor size and suppression of metastasis to critical organs such as the liver and lungs are observed. Crucially, the drug release mechanism is engineered to be responsive to the tumor microenvironment and is regulated by the overexpression of the enzymatic activity of matrix metalloproteinases (MMP2 and MMP9) in TNBC tumors, triggering the degradation of the hydrogel matrix, leading to controlled release of the immobilized therapeutic drug. This ensures that the therapeutic action is localized, reducing systemic toxicity and enhancing treatment efficacy. These findings suggest that this neoadjuvant approach holds promise for broader applications in other cancer types.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Institute of Medical Robotics, School of Biomedical Engineering, Shanghai Jiao Tong University, Shanghai, 200240, China.
- The Hamlyn Centre, Institute of Global Health Innovation, Imperial College London, London, South Kensington, SW7 2AZ, UK.
- Department of Metabolism, Digestion, and Reproduction, Faculty of Medicine, Imperial College London, London, SW7 2AZ, UK.
ORCID-Profile: Mingzhen Tian, Meysam Keshavarz, Ali Anil Demircali, Bing Han
Förderung
- Shanghai Municipal Science and Technology Major Project
Zitieren
APA
Tian, M., Keshavarz, M., Demircali, A. A., Han, B., & Yang, G. Z. (2025). Localized Microrobotic Delivery of Enzyme‐Responsive Hydrogel‐Immobilized Therapeutics to Suppress Triple‐Negative Breast Cancer. Small, 21(18). https://doi.org/10.1002/smll.202408813
Vancouver
Tian M, Keshavarz M, Demircali AA, Han B, Yang GZ. Localized Microrobotic Delivery of Enzyme‐Responsive Hydrogel‐Immobilized Therapeutics to Suppress Triple‐Negative Breast Cancer. Small. 2025;21(18). doi:10.1002/smll.202408813
BibTeX
@article{Tian2025,
author = {Tian, Mingzhen and Keshavarz, Meysam and Demircali, Ali Anil and Han, Bing and Yang, Guang-Zhong},
title = {Localized Microrobotic Delivery of Enzyme‐Responsive Hydrogel‐Immobilized Therapeutics to Suppress Triple‐Negative Breast Cancer},
journal = {Small},
year = {2025},
volume = {21},
number = {18},
doi = {10.1002/smll.202408813}
}
EUVIMED